TY - JOUR
T1 - Medical interventions for chronic rhinosinusitis in cystic fibrosis
AU - Karanth, Tulasi Kota
AU - Karanth, Veena Kota Laxminarayan KL
AU - Ward, Bryan K.
AU - Woodworth, Bradford A.
AU - Karanth, Laxminarayan
N1 - Funding Information:
We thank the management of Kasturba Medical College, Johns Hopkins University School of Medicine, and University of Alabama for giving us the opportunity to be involved in the completion of this protocol and review. We also thank Nikki Jahnke from the Cochrane Cystic Fibrosis and Genetic Disorders Group for her help with this protocol and review. This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
Funding Information:
National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (1 R01 HL133006-01) National Institute for Health Research, UK This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.
Funding Information:
BAW is a consultant for Olympus and Cook Medical and has grant support from the NHLBI and Cook Medical.
Publisher Copyright:
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2022/4/7
Y1 - 2022/4/7
N2 - Background: Chronic rhinosinusitis frequently occurs in people with cystic fibrosis. Several medical interventions are available for treating chronic rhinosinusitis in people with cystic fibrosis; for example, different concentrations of nasal saline irrigations, topical or oral corticosteroids, antibiotics - including nebulized antibiotics - dornase alfa and modulators of the cystic fibrosis transmembrane conductance regulator (CFTR) (such as lumacaftor, ivacaftor or tezacaftor). However, the efficacy of these interventions is unclear. This is an update of a previously published review. Objectives: The objective of this review is to compare the effects of different medical interventions in people diagnosed with cystic fibrosis and chronic rhinosinusitis. Search methods: We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and hand searching of journals and conference abstract books. Date of last search of trials register: 09 September 2021. We also searched ongoing trials databases, other medical databases and the reference lists of relevant articles and reviews. Date of latest additional searches: 22 November 2021. Selection criteria: Randomized and quasi-randomized trials of different medical interventions compared to each other or to no intervention or to placebo. Data collection and analysis: Two review authors independently assessed trials identified for potential inclusion in the review. We planned to conduct data collection and analysis in accordance with Cochrane methods and to independently rate the quality of the evidence for each outcome using the GRADE guidelines. Main results: We identified no trials that met the pre-defined inclusion criteria. The most recent searches identified 44 new references, none of which were eligible for inclusion in the current version of this review; 12 studies are listed as excluded and one as ongoing. Authors' conclusions: We identified no eligible trials assessing the medical interventions in people with cystic fibrosis and chronic rhinosinusitis. High-quality trials are needed which should assess the efficacy of different treatment options detailed above for managing chronic rhinosinusitis, preventing pulmonary exacerbations and improving quality of life in people with cystic fibrosis.
AB - Background: Chronic rhinosinusitis frequently occurs in people with cystic fibrosis. Several medical interventions are available for treating chronic rhinosinusitis in people with cystic fibrosis; for example, different concentrations of nasal saline irrigations, topical or oral corticosteroids, antibiotics - including nebulized antibiotics - dornase alfa and modulators of the cystic fibrosis transmembrane conductance regulator (CFTR) (such as lumacaftor, ivacaftor or tezacaftor). However, the efficacy of these interventions is unclear. This is an update of a previously published review. Objectives: The objective of this review is to compare the effects of different medical interventions in people diagnosed with cystic fibrosis and chronic rhinosinusitis. Search methods: We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and hand searching of journals and conference abstract books. Date of last search of trials register: 09 September 2021. We also searched ongoing trials databases, other medical databases and the reference lists of relevant articles and reviews. Date of latest additional searches: 22 November 2021. Selection criteria: Randomized and quasi-randomized trials of different medical interventions compared to each other or to no intervention or to placebo. Data collection and analysis: Two review authors independently assessed trials identified for potential inclusion in the review. We planned to conduct data collection and analysis in accordance with Cochrane methods and to independently rate the quality of the evidence for each outcome using the GRADE guidelines. Main results: We identified no trials that met the pre-defined inclusion criteria. The most recent searches identified 44 new references, none of which were eligible for inclusion in the current version of this review; 12 studies are listed as excluded and one as ongoing. Authors' conclusions: We identified no eligible trials assessing the medical interventions in people with cystic fibrosis and chronic rhinosinusitis. High-quality trials are needed which should assess the efficacy of different treatment options detailed above for managing chronic rhinosinusitis, preventing pulmonary exacerbations and improving quality of life in people with cystic fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=85127837179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127837179&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD012979.pub3
DO - 10.1002/14651858.CD012979.pub3
M3 - Review article
C2 - 35390177
AN - SCOPUS:85127837179
SN - 1465-1858
VL - 2022
SP - CD012979
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 4
M1 - CD012979
ER -